Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
41 hedge funds and large institutions have $4.96M invested in Enzo Biochem, Inc. in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.67% less ownership
Funds ownership: 26.27% → 25.61% (-0.67%)
9% less funds holding
Funds holding: 45 → 41 (-4)
49% less capital invested
Capital invested by funds: $9.8M → $4.96M (-$4.84M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$91.1K |
| 2 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$47.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.3K |
| 4 |
Squarepoint
New York
|
+$33.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$25.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$158K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$87K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$55.3K |
| 4 |
EGM
Engineers Gate Manager
New York
|
-$37.3K |
| 5 |
Millennium Management
New York
|
-$23.1K |
ENZ Hedge Fund Activity: Q1 2025 in Review
41 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2025, worth a combined $4.96M — down 49% from $9.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ENZ and 3 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, adding an estimated $91.1K. The largest seller was Renaissance Technologies, cutting an estimated $158K.
- 41 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2025, down from 45 in Q4 2024.
- Funds reported $4.96M of Enzo Biochem, Inc. stock for Q1 2025, down 49% quarter-over-quarter.
- 3 funds opened new Enzo Biochem, Inc. positions in Q1 2025 and 6 closed out, a net change of -3 holders.
- The largest Enzo Biochem, Inc. buyer in Q1 2025 was Citadel Advisors, an estimated $91.1K added.
- The largest Enzo Biochem, Inc. seller in Q1 2025 was Renaissance Technologies, an estimated $158K sold.
Based on aggregated 13F filings for Q1 2025.